Mapp 2019 contract

Ended Indefinite Delivery Contract Awarded Last action

Contract number
75A50119D00018
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 100% complete
IDV ceiling
$50,097,495.00
Award type
Single award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a single-award indefinite-delivery contract to Mapp Biopharmaceutical, Inc. on June 3, 2019, with a ceiling value of $50,097,495, expiring June 30, 2026. No set-aside was used. The contract funds research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats, including vaccines, therapeutics, diagnostics, respiratory protective devices, ventilators, and production platforms leading toward FDA approval or licensure. Work is performed at the contractor's location. The originating Broad Agency Announcement, posted in October 2017 with an award date of July 23, 2021, anticipated multiple awards ranging from $750,000 to $8 million depending on project scope. The contract period encompasses a base term plus options through its ultimate completion date. NAICS codes 541711 and 541712 and PSC codes R408 and R419 apply. A no-cost modification effective during the performance period revised Article G.7 regarding indirect cost rate.

Transactions

Action Obligated Date
Other Administrative Action P00022 · The purpose of this no-cost modification is to revise article g.7. Indirect cost rate. $0
Other Administrative Action P00021 · The purpose of this no-cost modification is to add attachment 11: transfer government furnish property (GFP) from HHSO100201900018C to 75A50122C00076. $0
Other Administrative Action P00020 · The purpose of this no-cost modification is to 1. Extend clin 0003 period of performance from 30 SEP 2025 to 30 JUN 2026 and 2. Revise primary and alternate… $0
Other Administrative Action P00019 · The purpose of this no-cost modification is to revise article g.7. Indirect cost rate $0
Other Administrative Action P00018 · The purpose this no cost modification is to: 1) extend the period of performance for clin 0003 through september 30, 2025 and 2) add attachment 09 - EO far… $0
Other Administrative Action P00017 · No cost modification to change primary and secondary COR. $0
Other Administrative Action P00016 · No cost modification to revise the statement of work. $0
Other Administrative Action P00015 · No cost modification to revise the provisional rates for section g.7 indirect cost rates. $0
Other Administrative Action P00014 · Unilateral no cost modification to correct delivery date errors within prism, to enable mapp biopharmaceutical's invoicing in the invoice processing platform… $0
Other Administrative Action P00013 · No-cost modification is to transfer government furnished property (GFP) from HHSO100201900018C to 75A50122C00076. $0
Other Administrative Action P00012 · Revise indirect rates and add far clause 52.204-27 $0
Other Administrative Action P00011 · Mapp biopharmaceutical - transfer GFP to to contract 75A50122C00076. $0
Funding Only Action P00010 · Mapp biopharmaceutical - supplemental funding for clin 0001 indirect rates. $720,008
Other Administrative Action P00009 · Mapp biopharmaceutical - revise base period clin 00001 IAW modification P00005. $0
Other Administrative Action P00008 · Revise indirect cost rates and invoice submission instructions. $0
Other Administrative Action P00007 · Revise statement of work (SOW). $0
Other Administrative Action P00006 · Transfer government furnished property to HHSO100201600021C and additional administrative revisions. $0
Other Administrative Action P00005 · Exercise clin 0003 phase 1 clinical study $7,308,750
Supplemental Agreement for work within scope P00004 · Modify article g.7. Indirect rates update CO assignment $0
Other Administrative Action P00003 · Add alternate COR to contract $0
Supplemental Agreement for work within scope P00002 · Exercise clin 0002, option 1 for the advanced development of an anti-marburg virus (MBP091) medical countermeasure $12,978,434
Supplemental Agreement for work within scope P00001 · Development of an anti?marburg virus (MBP091) medical countermeasure $0
Original award $16,504,199
Show all 23

Quick answers

Who was awarded contract 75A50119D00018?

75A50119D00018 was awarded to Mapp Biopharmaceutical, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on June 3, 2019.

How much is contract 75A50119D00018 worth?

75A50119D00018's own ceiling is $50,097,495.

Who can order from contract 75A50119D00018?

75A50119D00018 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75A50119D00018 competed?

The extent of competition for 75A50119D00018 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login